Glioma, Malignant
70
20
28
14
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.6%
6 terminated out of 70 trials
70.0%
-16.5% vs benchmark
1%
1 trials in Phase 3/4
14%
2 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (70)
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Window of Opportunity Study of DSP-0390 in Gliomas
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
CUE-102 in Recurrent Glioblastoma
Niraparib In Recurrent IDH 1/2 Gliomas
An Integrated Radio-immunological Approach
Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma
18F-Fluciclovine PET-MRI in High-grade Glioma
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Imaging of Solid Tumors Using 18F-TRX
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma